Free Trial
NASDAQ:VINC

Vincerx Pharma Q2 2023 Earnings Report

Vincerx Pharma logo
$0.04 -0.01 (-11.59%)
As of 09:32 AM Eastern

Vincerx Pharma EPS Results

Actual EPS
-$10.40
Consensus EPS
-$13.00
Beat/Miss
Beat by +$2.60
One Year Ago EPS
N/A

Vincerx Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vincerx Pharma Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Monday, August 7, 2023
Conference Call Time
8:00AM ET

Upcoming Earnings

Vincerx Pharma's Q1 2025 earnings is scheduled for Wednesday, August 6, 2025

Vincerx Pharma Earnings Headlines

Vincerx Pharma announces plan to delist from Nasdaq
The MAGA 7 Stocks: Huge Upside in 2025
The Trump economy is back in full force, and it’s creating huge opportunities for investors. With Trump pushing for lower taxes, fewer regulations, tariffs on foreign competitors, and domestic manufacturing dominance, some stocks are set to skyrocket in value—while others will be left behind. That’s why we put together this free report revealing the 7 MAGA stocks poised to thrive in 2025.
See More Vincerx Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vincerx Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vincerx Pharma and other key companies, straight to your email.

About Vincerx Pharma

Vincerx Pharma (NASDAQ:VINC), a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

View Vincerx Pharma Profile

More Earnings Resources from MarketBeat